NIRT MONITOR (876505)

  https://cordis.europa.eu/project/id/876505

  Horizon 2020 (2014-2020)

  ACCURATE EASY-TO-USE AND NON-INVASIVE DEVICE FOR EARLY DETECTION AND MONITORING OF HEART FAILURE IN REAL TIME

  SME instrument (EIC-SMEInst-2018-2020)

  internal medicine  ·  business models  ·  cardiology

  2019-08-01 Start Date (YY-MM-DD)

  2019-11-30 End Date (YY-MM-DD)

  € 71,429 Total Cost

  Description

Heart Failure (HF) affects 15 million of Europeans and €6.41 billion are annually spent on its management and treatment by the healthcare system, CORALERT aims to favour the HF prevention and decrease its costs through its innovative NIRT MONITOR medical device. Gold standard procedures for diagnosing HF using catheterization are risky and complexes. As validated by clinical assay, NIRT MONITOR offers an alternative, safe and easy to use method to early diagnosis HF in real time by non-invasive measuring of LVEDP (Left Ventricular End Diastolic Pressure) providing physicians and in- and out-patient settings an early diagnosis of HF and its complications. NIRT MONITOR will improve the quality of life of patients while reducing hospitalizations by 30% and re-admissions by 80%. Cardiology, ICU, ER and Internal Medicine Units from hospitals (€5.1 billion of European market), GP offices and homecare settings will be the target users. NIRT MONITOR business model will be based on devices sales/leasing for early adopters and later from indirect sales/leasing through medical technology distributors. Revenues will be also generated by direct and indirect sales of disposables and by Cloud App payment fees. NIRT MONITOR will be an inexpensive solution (€10,000/device) in comparison with one catheter lab procedure (first two uses will save the 100% of the costs of one use of the standard method). NIRT MONITOR´s safety, easy to use, cost-efficient and accuracy will ensure its penetration into targeted European countries (Spain, France and Germany) and expansion over other European countries and US. We estimate a profit of ≈€38.5M after four years of commercialization with a ROI of 11.8 and a market share of 4.5%. We have filled US and PCT patent applications. To ensure the sucessful release of NIRT MONITOR into the market, a feasibility study will be performed during SME Phase 1 to evaluate any technical, commercial and financial issues related to the project.

  Complicit Organisations

1 Israeli organisation participates in NIRT MONITOR.